期刊文献+

1例左氧氟沙星氯化钠注射液致尖端扭转型室性心动过速的用药分析与药学监护 被引量:4

Medication analysis and pharmaceutical care on a case of torsade de pointes caused by levofloxacin and sodium chloride injection
下载PDF
导出
摘要 1例82岁男性患者,入院诊断为"冠心病、严重心力衰竭合并双肺感染4个月余",入院后先后给予哌拉西林舒巴坦钠(2.5 g,q 12 h,ivgtt)、头孢哌酮钠舒巴坦钠(3 g,q 12 h,ivgtt)抗感染治疗,疗效欠佳。后咳嗽咳痰加重,痰培养结果为嗜麦芽窄食单胞菌,全院会诊建议选用左氧氟沙星(0.5 g,q 24 h,ivgtt),临床药师考虑到患者具有多个QT间期延长的危险因素建议谨慎选用对QT间期有影响的药物,应严密监测患者的QTc变化,并根据肾功能调整药物剂量(0.5 g,q 48 h,ivgtt)。治疗9 d后患者发生尖端扭转型室性心动过速(TdP)。临床药师给予患者全程药学监护,协助医师及时确定导致TdP的药物,停用左氧氟沙星氯化钠注射液并补充血钾防治严重心律失常复发,停药4 d后患者QT间期逐渐恢复至正常值,病情控制平稳,未再出现新的严重心律失常。 One 82-year-old male patient was admitted into hospital and diagnosed as coronary heart disease,severe heart failure and pneumonia.After admission,piperacillin sodium and sulbactam sodium(2.5 g,q 12 h,ivgtt),cefoperazone sodium and sulbactam sodium(3 g,q 12 h,ivgtt)were successively given to the patient but had poor effect.Cough and expectoration aggravated and the result of sputum culture showed Stenotrophomonas maltophilia.Levofloxacin(0.5 g,q 24 h,ivgtt)was recommended according to the hospital consultation.Considering that the patient had several risk factors of QT interval prolongation,clinical pharmacists suggested that drugs associated with QT interval prolongation should be carefully selected,changes of QTc should be monitored during the treatment,and the dose of levofloxacin should be adjusted to 0.5 g,q 48 h according to the renal function of the patient.The patient developed torsades de pointes(TdP)9 days later.Clinical pharmacist carried out the whole range of pharmaceutical care on the patient by helping physicians determine the drug causing TdP in time,stop levofloxacin and supply blood potassium to prevent the recurrence of serious arrhythmia.The QT interval of patient gradually returned to normal range 4 days later.The patient's condition was stable and no new serious arrhythmia appeared again.
作者 胡文君 陆璐 张青霞 HU Wen-jun;LU Lu;ZHANG Qing-xia(Department of Pharmacy,Xuanwu Hospital,Capital Medical University,Beijing 100053,China;Department of Pharmacy,Fengtai Maternal&Child Health Hospital,Beijing 100069,China;National Clinical Research Center for Geriatric Disorders,Beijing 100053,China)
出处 《中国药物应用与监测》 CAS 2020年第3期166-169,共4页 Chinese Journal of Drug Application and Monitoring
基金 北京市科学技术委员会“老年人多重用药管理模式的建立与临床应用研究”专项资助课题(D181100000218002) 北京市卫生和计划生育委员会“老年重大疾病关键技术研究”(PXM2018_026283_000002)。
关键词 左氧氟沙星 QT间期 尖端扭转型室性心动过速 药学监护 Levofloxacin QT interval Torsades de pointes Pharmaceutical care
  • 相关文献

参考文献6

二级参考文献42

  • 1柴栋,王睿.氟喹诺酮类抗菌药物所致心肌传导紊乱[J].中国药物应用与监测,2005,2(5):12-14. 被引量:5
  • 2Daniel Liu.ICH E14:一项新的评价新药研发中药物临床心脏安全性的国际药政法规[J].中国临床药理学与治疗学,2006,11(1):116-120. 被引量:7
  • 3卫生部合理用药专家委员会.中国医师药师临床用药指南[M].重庆:重庆出版集团重庆出版社,2009:700-701.
  • 4Frothingham R.Quinolone safety and efficacy[J].Emerg Infect Dis,2005,11(6):985-987.
  • 5Prabhakar M,Krahn AD.Ciprofloxacin-induced acquired long QT syndrome[J].Heart Rhythm,2004,1(5):624-626.
  • 6Flanagan MC,Mitchell ES,Haigney MCP.Ciprofloxacininduced torsade de pointes[J].Int J Cardiol,2006,113(2):239-241.
  • 7Daya SK,Gowda RM,Khan IA.Ciprofloxacin-and hypocalcemia-induced torsade de pointes triggered by hemodialysis[J].Am J Ther,2004,11(1):77-79.
  • 8Amankwa K,Krishnan SC,Tisdale JE.Torsades de pointes associated with fluoroquinolones:importance of concomitant risk factors[J].Clin Pharmacol Ther,2004,75(3):242-247.
  • 9Gandhi PJ,Menezes PA,Vu HT,et al.Fluconazole-and levofloxacin-induced torsades de pointes in an intensive care unit patient[J].Am J Health Syst Pharm,2003,60(23):2479-2483.
  • 10Fteha A,Fteha E,Haq S,et al.Gatifloxacin induced torsades de pointes[J].Pacing Clin Electrophysiol,2004,27(10):1449-1450.

共引文献1163

同被引文献39

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部